8-K: Pyxis Oncology Appoints Thomas Civik CEO & Chairman

Pyxis Oncology has appointed Thomas Civik as its permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, reinforcing its focus on advancing its MICVO program.

Summary

• Thomas Civik has been officially appointed as the permanent Chief Executive Officer and Chairman of the Board of Pyxis Oncology, Inc., effective September 4, 2026.
• Civik, who has been serving as Interim CEO since February 2, 2026, will continue to serve on the Board.
• John Flavin, co-founder and founding Chairman, will transition to Lead Independent Director.
• The company is advancing its lead candidate, micvotabart pelidotin (MICVO), a novel antibody-drug conjugate targeting extradomain-B of fibronectin (EDB+FN).
• Updated data from the MICVO Phase 1 monotherapy study in head and neck squamous cell carcinoma (HNSCC) is expected in Fall 2026.
• Updated data from the Phase 1/2 combination study with pembrolizumab in first-line HNSCC is expected in Q4 2026.
• Dr. Santhosh Palani resigned from the Board of Directors, effective September 4, 2026, due to increased professional commitments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating leadership stability and a clear strategic direction for advancing key clinical programs.

Positives

• Appointment of Thomas Civik as permanent CEO and Chairman provides leadership stability.
• Civik's extensive experience in the biotechnology sector, including leadership roles at Genentech and Five Prime Therapeutics, is a significant asset.
• The transition of John Flavin to Lead Independent Director ensures continued experienced oversight.
• The company is advancing its lead candidate, MICVO, with clear clinical milestones ahead.
• MICVO has received Fast Track Designation from the FDA for R/M HNSCC.
• The company expects to report updated clinical data for MICVO in Fall and Q4 2026, providing crucial insights into its potential.
• Vesting acceleration and extended option exercise periods for Dr. Palani's equity awards recognize his contributions.

Negatives

• The resignation of Dr. Santhosh Palani reduces the Board's size from eight to seven members.

Risks

• The company's success is dependent on the clinical development and potential commercialization of MICVO, which is still in Phase 1/2 trials.
• The forward-looking statements are subject to inherent uncertainties and risks, including those detailed in the company's SEC filings, which could cause actual results to differ materially.
• New risk factors may emerge over time, and the company's management cannot predict all potential risks or their impact.

Future Outlook

The company anticipates reporting updated clinical data for its lead candidate, MICVO, in both monotherapy and combination studies during Fall 2026 and Q4 2026, respectively. These updates are expected to provide detailed analysis of safety, tolerability, efficacy, and initial durability.

Management Comments

• "Over the past several months, Tom has demonstrated the leadership, strategic focus and disciplined execution the Board believes are needed as Pyxis Oncology approaches key clinical milestones for MICVO."
• "He brings a deep understanding of the Company, its science and its strategy, and during his time as Interim Chief Executive Officer, the Company has continued to advance MICVO, strengthen its financial position and remain focused on generating the clinical evidence needed to evaluate MICVOs potential for patients."
• "The Board has full confidence in Tom and is pleased to appoint him Chief Executive Officer and Chairman of the Board."
• "I am honored by the Boards confidence and proud to continue leading Pyxis Oncology at such an important time for the Company."
• "I want to thank John for his tremendous leadership and commitment to Pyxis Oncology. His vision and guidance have helped shape the Company from its earliest days, and I am grateful that we will continue to benefit from his experience and perspective as Lead Independent Director."
• "Our extraordinary team at Pyxis Oncology has executed with speed, precision, and a deep commitment to finding new treatment options for difficult-to-treat cancers. With important clinical milestones ahead, our focus remains on generating the clinical evidence needed to evaluate MICVOs potential to address the significant unmet need in head and neck cancer. I look forward to working alongside our talented team as we continue to execute on our strategy and deliver meaningful progress for patients while building long-term value for shareholders."

Industry Context

StockSavvy.ai notes that the appointment of a permanent CEO and Chairman, especially one with extensive experience like Thomas Civik, is a common and positive step for clinical-stage biopharmaceutical companies as they approach critical clinical milestones. This leadership stability is crucial for navigating the complex drug development process and attracting potential investment.

Management Changes

Corporate Governance

Related Party Transactions

• There are no family relationships between Mr. Civik and any other director or executive officer of the Company.
• Neither Mr. Civik nor any member of his immediate family has any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: Benefit from leadership stability and continued focus on advancing clinical programs, potentially leading to long-term value creation.
• Employees: Benefit from clear leadership direction and continued focus on the company's mission.
• Board of Directors: Experience a shift in leadership structure and committee composition.

Next Steps

• Advance the clinical development of MICVO through ongoing Phase 1 monotherapy and Phase 1/2 combination studies.
• Report updated clinical data from the MICVO Phase 1 monotherapy study in Fall 2026.
• Report updated clinical data from the MICVO Phase 1/2 combination study in Q4 2026.
• File the Amendment to the Interim Chief Executive Officer Employment Agreement as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.

Key Dates

Recommendation

The appointment of a permanent CEO and Chairman is a positive step for leadership stability, and the company is progressing with its clinical trials. However, the company remains in the clinical-stage, and significant value realization is contingent on future clinical data and regulatory approvals. Therefore, a 'hold' recommendation is appropriate pending further clinical data.

Keywords

Pyxis Oncology, Thomas Civik, CEO Appointment, Chairman, MICVO, Head and Neck Cancer, Biotechnology, Clinical Trials